DOT1L and acute myeloid leukemia: CD33 targeted agent + anthracycline and cytarabine-based chemotherapy (tested in patients with KMT2Ar AML, subtype unspecified) (Pollard et al., 2021); DOT1L inhibitor + standard chemotherapy (NCT03724084) (tested in patients with newly diagnosed KMT2Ar AML, subtype unspecified) (Yi and Ge, 2022); DOT1L inhibitor + DNMT inhibitor (NCT03701295) (tested in patients with relapsed, refractory, or newly diagnosed KMT2Ar AML, subtype unspecified) (Yi and Ge, 2022)